A PILOT STUDY OF NY-ESO PLUS CPG 7909 AND MONTANIDE IN PATIENTS WITH CANCER

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。为了产生比以往临床研究更强、更具临床相关性的NY-ESO-1免疫，将HLA-A2限制性NY-ESO-1b肽（SLLMWITQC; position 157-165）与Montanide ISA（商标）51 + CpG 7909混合，皮下注射给表达NY-ESO-1或lge -1抗原的HLA-A2癌症患者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In an attempt to generate stronger and more clinically relevant NY-ESO-1 immunity than in previous clinical studies, the HLA-A2 restricted NY-ESO-1b peptide (SLLMWITQC; position 157-165) will be mixed with Montanide ISA(Trademark) 51 plus CpG 7909 and given by subcutaneous injection to HLA-A2 patients with cancer expressing the NY-ESO-1 or LAGE-1 antigen.